2-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}pyrimidine-5-carboxylic acid | 1020658-28-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}pyrimidine-5-carboxylic acid
• 英文别名: 2-[5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl]pyrimidine-5-carboxylic acid
• CAS: 1020658-28-9
• 化学式: C₁₈H₁₅BrFN₅O₃S
• 分子量: 480.317
• InChiKey: LIJPQOUOVXIEPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  methyl 2-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}pyrimidine-5-carboxylate 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 0.17h， 生成 2-{5-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-1,3,4-thiadiazol-2-yl}pyrimidine-5-carboxylic acid
  参考文献：
  名称：

  WO2008/46226

  摘要：

  公开号：

文献信息

• NOVEL CYCLOBUTYL COMPOUNDS AS KINASE INHIBITORS
  申请人：Heinrich Timo

  公开号：US20100160356A1

  公开（公告）日：2010-06-24

  The invention relates to compounds of the formula I, to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the formation or course of which protein kinases are involved.

  该发明涉及公式I的化合物，以及用于制备治疗疾病的药物的制备和使用方法，特别是用于治疗肿瘤和/或蛋白激酶参与形成或发展的疾病。
• AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Oballa Renata M.

  公开号：US20100004245A1

  公开（公告）日：2010-01-07

  Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的Azacycloalkane衍生物是选择性抑制stearoyl-coenzyme A delta-9去饱和酶（SCD1）相对于其他已知的stearoyl-coenzyme A去饱和酶的化合物。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。
• NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3486244A1

  公开（公告）日：2019-05-22

  The present invention relates to a new compound having an FGFR inhibitory activity and preparation and application thereof. In particular, the compound according to the present invention has a structure as shown in formula I, wherein each group and substituent are as defined in the description. Also disclosed in the present invention are a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease.

  本发明涉及一种具有 FGFR 抑制活性的新化合物及其制备和应用。特别是，根据本发明的化合物具有如式 I 所示的结构，其中各基团和取代基如描述中所定义。本发明还公开了该化合物的制备方法及其在制备治疗和/或预防肿瘤相关疾病和/或FGFR相关疾病的药物中的用途。
• Heterocyclic compounds, their production and use
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0733633B1

  公开（公告）日：2003-05-28
• [EN] AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] Dérivés d'azacycloalcane en tant qu'inhibiteurs de la stéaroyl-coenzyme A delta-9 désaturase
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2008046226A1

  公开（公告）日：2008-04-24

  [EN] Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
  [FR] L'invention concerne des dérivés d'azacycloalcane de formule structurale (I), lesdits dérivés étant des inhibiteurs sélectifs de la stéaroyl-coenzyme A delta-9 désaturase (SCD1) par rapport à d'autres stéaroyl-coenzyme A désaturases connues. Les composés selon la présente invention sont utiles pour la prévention et le traitement de maladies associées à une synthèse et un métabolisme lipidiques anormaux, notamment les maladies cardiovasculaires, telles que l'athérosclérose ; l'obésité ; le diabète ; les maladies neurologiques ; le syndrome métabolique ; la résistance à l'insuline ; et la stéatose du foie.